Danaher Co. (NYSE:DHR) Shares Sold by Kingswood Wealth Advisors LLC

Kingswood Wealth Advisors LLC trimmed its position in Danaher Co. (NYSE:DHR) by 69.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,410 shares of the conglomerate’s stock after selling 7,729 shares during the period. Kingswood Wealth Advisors LLC’s holdings in Danaher were worth $783,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Coronation Fund Managers Ltd. lifted its position in shares of Danaher by 29.9% during the 2nd quarter. Coronation Fund Managers Ltd. now owns 6,389 shares of the conglomerate’s stock valued at $1,596,000 after acquiring an additional 1,470 shares during the last quarter. Ascent Group LLC lifted its position in shares of Danaher by 30.2% during the 2nd quarter. Ascent Group LLC now owns 2,205 shares of the conglomerate’s stock valued at $551,000 after acquiring an additional 512 shares during the last quarter. Quarry LP lifted its position in shares of Danaher by 250.6% during the 2nd quarter. Quarry LP now owns 298 shares of the conglomerate’s stock valued at $74,000 after acquiring an additional 213 shares during the last quarter. Regal Investment Advisors LLC lifted its position in shares of Danaher by 1.9% during the 2nd quarter. Regal Investment Advisors LLC now owns 8,581 shares of the conglomerate’s stock valued at $2,144,000 after acquiring an additional 157 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. lifted its position in shares of Danaher by 5.0% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 11,035 shares of the conglomerate’s stock valued at $2,760,000 after acquiring an additional 527 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Down 1.1 %

Danaher stock opened at $247.77 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company has a market capitalization of $178.96 billion, a price-to-earnings ratio of 47.29, a PEG ratio of 4.43 and a beta of 0.83. Danaher Co. has a one year low of $225.42 and a one year high of $281.70. The company’s fifty day moving average price is $235.75 and its two-hundred day moving average price is $253.65.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Stifel Nicolaus increased their price objective on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday, October 23rd. Royal Bank of Canada cut their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price on the stock in a research note on Friday, December 13th. JPMorgan Chase & Co. cut their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, TD Cowen boosted their target price on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $285.81.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.